The initial commercial dispatch, valued at approximately ₹50 crore, was successfully completed during Q1FY2026-27. This not only validates Morepen’s operational readiness but also underscores its capability to handle large-scale, long-duration manufacturing partnerships. Mr. Sanjay Suri, Managing Director, highlighted the importance of this moment, stating, “This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer… we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”
Looking ahead, the company is poised for accelerated growth. Morepen anticipates additional supplies worth approximately ₹225 crore during Q2FY2026-27, subject to customer schedules and regulatory requirements. To support this ambitious growth trajectory and future CDMO opportunities, Morepen is aggressively strengthening its manufacturing infrastructure. Total reactor capacity is projected to reach approximately 600 KL by the end of Q2, with further expansions planned to 800 KL and an ambitious 1,000 KL in subsequent phases.
This strategic move reinforces Morepen’s commitment to building a scalable CDMO platform, deepening customer relationships, and carving out a significant position in the global pharmaceutical manufacturing landscape. For investors, this signals a robust strategic shift, promising sustained revenue streams and enhanced long-term value creation.